A Phase 2 Trial of Everolimus and Pasireotide Long Acting Release in Patients with Metastatic Uveal Melanoma

OBJECTIVES: Test the hypothesis that inhibiting mammalian target of rapamycin (mTOR) and Insulin Growth Factor-1 Receptor would be efficacious in metastatic uveal melanoma. METHODS: Phase 2 trial of everolimus 10mg daily plus pasireotide long-acting release 60mg every 28 days enrolling patients with...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Melanoma Res
Autori principali: Shoushtari, Alexander N., Ong, Leonard T., Schoder, Heiko, Singh-Kandah, Shahnaz, Abbate, Kelly, Postow, Michael A., Callahan, Margaret K., Wolchok, Jedd, Chapman, Paul B., Panageas, Katherine S., Schwartz, Gary K., Carvajal, Richard D.
Natura: Artigo
Lingua:Inglês
Pubblicazione: 2016
Soggetti:
Article
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC5553199/
https://ncbi.nlm.nih.gov/pubmed/26795274
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/CMR.0000000000000234
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi